Cargando…

Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have become a first-choice therapy option in the treatment of clear cell renal cell carcinoma (ccRCC). A predictive biomarker is urgently needed since not all patients respond and adverse events occur. Therefore, an ex vivo tissue slice culture (TS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stenzel, Philipp J., Hörner, Nina, Foersch, Sebastian, Wagner, Daniel-Christoph, Tsaur, Igor, Thomas, Anita, Haferkamp, Axel, Macher-Goeppinger, Stephan, Roth, Wilfried, Porubsky, Stefan, Tagscherer, Katrin E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471479/ https://www.ncbi.nlm.nih.gov/pubmed/34572738 http://dx.doi.org/10.3390/cancers13184511

Ejemplares similares

Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma
por: Stenzel, Philipp J., et al.
Publicado: (2019)

Prognostic relevance of androgen receptor expression in renal cell carcinomas
por: Foersch, Sebastian, et al.
Publicado: (2017)

The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma
por: Weissinger, Daniel, et al.
Publicado: (2013)

Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2021)

Expression and Functional Characterization of the BNIP3 Protein in Renal Cell Carcinomas
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2017)

Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma
por: Radspieler, Melissa Marie, et al.
Publicado: (2019)

MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen
por: Tagscherer, Katrin E., et al.
Publicado: (2016)

Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer
por: Martin, Steve Z., et al.
Publicado: (2019)

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2016)

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
por: Wagener, Nina, et al.
Publicado: (2010)

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2022)

Senescence-Associated Molecules and Tumor-Immune-Interactions as Prognostic Biomarkers in Colorectal Cancer
por: Kellers, Franziska, et al.
Publicado: (2022)

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker
por: Knoll, Maximilian, et al.
Publicado: (2015)

Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology
por: Borgmann, Hendrik, et al.
Publicado: (2021)

Multimodal Deep Learning for Prognosis Prediction in Renal Cancer
por: Schulz, Stefan, et al.
Publicado: (2021)

EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells
por: Fussbroich, Bettina, et al.
Publicado: (2011)

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications()
por: Zhou, Xiaoguang, et al.
Publicado: (2015)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G
por: Suyama, Takayuki, et al.
Publicado: (2018)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
por: Juengel, Eva, et al.
Publicado: (2013)

Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
por: Markowitsch, Sascha D., et al.
Publicado: (2022)

PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity
por: Ferrata, Martina, et al.
Publicado: (2019)

Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2014)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients
por: Wagener, N, et al.
Publicado: (2013)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction
por: Zhao, Fuguang, et al.
Publicado: (2020)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
por: Makarević, Jasmina, et al.
Publicado: (2014)

Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
por: Juengel, Eva, et al.
Publicado: (2019)

Myofasziitis unter Nivolumab-Therapie
por: Krusche, M., et al.
Publicado: (2021)

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
por: Xie, Hui, et al.
Publicado: (2022)

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells
por: Makarević, Jasmina, et al.
Publicado: (2014)

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
por: Fessas, Petros, et al.
Publicado: (2017)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
por: Wedel, Steffen, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_21g05muj9goli6vm98k3optrbg